OA: Genome‑wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer (Review)

(Review)
  (click on pdf for full view)
 

Cancer typically develops due to genetic abnormalities, but a single gene abnormality cannot completely account for the onset of cancer. The Cancer Genome Atlas (CGA) project was conducted for the cross‑sectional genome‑wide analysis of numerous genetic abnormalities in various types of cancer. This approach has facilitated the identification of novel AT‑rich interaction domain 1A gene mutations in ovarian clear cell carcinoma, frequent tumor protein 53 (TP53) gene mutations in high‑grade ovarian serous carcinoma, and Kirsten rat sarcoma and B‑rapidly accelerated fibrosarcoma proto‑oncogene, serine/threonine kinase gene mutations in low‑grade ovarian serous carcinoma. Genome‑wide analysis of endometrial cancers has led to the establishment of four subgroups: Polymerase ultramutated, microsatellite instability hypermutated, genome copy‑number low and genome copy‑number high. These results may facilitate the improvement of the prediction of patient prognosis and therapeutic sensitivity in various types of gynecologic cancer. The enhanced use of currently available therapeutic agents and the development of novel drugs may be facilitated by the novel classification of ovarian cancer based on TP53 mutations, the efficacy of poly (ADP‑ribose) polymerase inhibitors for tumors with breast cancer 1/2 mutations and the effect of phosphoinositide‑3‑kinase (PI3K)/mammalian target of rapamycin inhibitors for tumors with mutations in the PI3K/protein kinase B signaling pathway. Important results have been revealed by genome‑wide analyses; however, the pathogenic underlying mechanisms of gynecologic cancer will require further studies and multilateral evaluation using epigenetic, transcriptomic and proteomic analyses, in addition to genomic analysis.

Related Articles

• ARID1A gene mutation in ovarian and endometrial cancers (Review)
• Amplification of the bromodomain-containing protein 4 gene in ovarian high‑grade serous carcinoma is associated with worse prognosis and survival
• Aurora kinase inhibitors: Potential molecular‑targeted drugs for gynecologic malignant tumors (Review)
• Improved survival associated with somatic PIK3CA mutations in copy‑number low endometrioid endometrial adenocarcinoma
• TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma